ARS Pharmaceuticals, Inc. SPRY 深 沪
等待开盘 05-21 09:30:00 美东时间
7.55
+0.380
+5.30%
华盛通- 最 高7.615
- 今 开7.21
- 成交量 51.66万股
- 最 低 7.19
- 昨 收 7.17
- 总市值 7.50亿
- 52周最高 18.90
- 市盈率 静 --
- 换手率 0.52%
- 52周最低 6.66
- 委 比 -55.03%
- 总股本 9930.33万
- 历史最高 63.41
- 量 比 0.45
- 振 幅 5.93%
- 历史最低 2.55
- 每 手 1
- 风险率 3.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多电话会总结 ｜ ARS Pharma(SPRY)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据ARS Pharmaceuticals业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总营收：8,430万美元，包括： - 美国净产品营收：7,220万美元（首个完整商业化年度） - 合作协议营收：970万美元 - 供应营收：240万美元 **成本与费用：** - 销售及管理费用（SG&A）：2.301亿美元，主要用于商业化投资，包括销售团队和直接面向消费者（DTC）营销活动 - 研发费用（R&D）：1,320万美元，主要用于产品开发和临床试验执行 **毛利率指标：** - 毛净比率（Gross t
05-16 12:03
ARS Pharmaceuticals Q1 2026 Earnings Call Transcript
ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter financial results on F...
05-15 21:31
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q1 financial results.
ARS Pharmaceuticals shares are trading lower after the company reported mixed Q...
05-15 20:48
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
财报速睇 | ARS Pharmaceuticals, Inc. 2026财年Q1营收0.23亿美元，同比增长184.5%；归母净利润亏损0.61亿美元，同比亏损扩大78.6%
华盛资讯5月15日讯，ARS Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收0.23亿美元，同比增长184.5%，归母净利润亏损0.61亿美元，同比亏损扩大78.6%。
05-15 19:02
财报速睇 | ARS Pharmaceuticals, Inc. 2026财年Q1营收0.23亿美元，同比增长187.5%；归母净利润亏损0.61亿美元，同比亏损扩大79.4%
华盛资讯5月15日讯，ARS Pharmaceuticals, Inc.公布2026财年Q1业绩，公司Q1营收0.23亿美元，同比增长187.5%，归母净利润亏损0.61亿美元，同比亏损扩大79.4%。
05-15 18:46
ARS Pharma Q1 FY26 net loss widens to $60.62 million; revenue more than doubled to $22.68 million
ARS Pharma Q1 FY26 net loss widens to $60.62 million; revenue more than doubled to $22.68 million ARS Pharmaceuticals posted Q1 net loss of USD 60.62 million, widening 79% from year-earlier period as revenue more than doubled to USD 22.68 million. Product revenue, net climbed 125% to USD 17.45 milli
05-15 18:23
ARS Pharma Q1 FY26 net loss widens to $60.6 million; revenue rises to $22.7 million
ARS Pharma Q1 FY26 net loss widens to $60.6 million; revenue rises to $22.7 million ARS Pharmaceuticals posted Q1 2026 revenue of USD 22.7 million, including USD 17.5 million in U.S. net product revenue from neffy. Net loss widened to USD 60.6 million, or USD 0.61 per share. SG&A expenses climbed to
05-15 18:21
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth
ARS Pharmaceuticals Q1 revenue beats estimates on neffy sales growth Overview U.S. biopharma firm's Q1 revenue rose yr/yr, beating analyst expectations Company's Q1 net loss widened as operating expenses rose on sales force expansion, marketing Sales force expansion to 148 representatives completed;
05-15 18:12
ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 74.29 percent decrease over losses of $(0.35) per share
05-15 18:03
